Couse J F, Curtis S W, Washburn T F, Lindzey J, Golding T S, Lubahn D B, Smithies O, Korach K S
Receptor Biology Section, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
Mol Endocrinol. 1995 Nov;9(11):1441-54. doi: 10.1210/mend.9.11.8584021.
We employed homologous recombination in mouse embryonic stem cells to disrupt the estrogen receptor (ER) gene. Subsequently generated mice that are homozygous for the gene disruption, termed ERKO, possess no demonstrable wild-type ER by Western blot analysis. However, the presence of residual high affinity binding, as detected by [3H]estradiol binding assays and sucrose gradients in uterine extracts from ERKO females prompted further investigation of transcription and translation products from the disrupted ER gene. Analysis of ERKO uterine messenger RNA (mRNA) by reverse transcriptase-polymerase chain reaction demonstrated that although no full-length wild-type ER mRNA was present, two smaller transcripts, labeled E1 and E2, were identified and partially sequenced. Both ERKO transcripts are splicing variants that result in the disrupting NEO sequence being partially or completely removed from the mRNA. In the ERKO-E2 variant, this results in a frame shift and the creation of at least two stop codons downstream. In the ERKO-E1 variant, the ER reading frame is preserved and encodes for a smaller mutant ER that could be the source of the residual estradiol binding. When this mutant form is overexpressed and characterized in vitro, it results in a smaller protein of the predicted size that possesses significantly reduced estrogen-dependent transcriptional activity compared with that of the wild-type ER. Despite residual amounts of an impaired ER variant, estrogen insensitivity in the female ERKOs was confirmed by the failure of estrogen treatment to induce known uterine markers of estrogen action, such as increased DNA synthesis, and transcription of the progesterone receptor, lactoferrin, and glucose-6-phosphate dehydrogenase genes. Furthermore, serum levels of estradiol in the ERKO female are more than 10-fold higher than those in the wild type, consistent with a syndrome of hormone insensitivity.
我们利用小鼠胚胎干细胞中的同源重组来破坏雌激素受体(ER)基因。随后产生的该基因破坏纯合子小鼠,称为ERKO,通过蛋白质免疫印迹分析未检测到可证实的野生型ER。然而,通过[3H]雌二醇结合试验和蔗糖梯度在ERKO雌性小鼠子宫提取物中检测到的残留高亲和力结合,促使对破坏的ER基因的转录和翻译产物进行进一步研究。通过逆转录-聚合酶链反应分析ERKO子宫信使核糖核酸(mRNA)表明,虽然不存在全长野生型ER mRNA,但鉴定出两个较小的转录本,标记为E1和E2,并进行了部分测序。两种ERKO转录本都是剪接变体,导致破坏的新霉素序列从mRNA中部分或完全去除。在ERKO-E2变体中,这导致移码并在下游产生至少两个终止密码子。在ERKO-E1变体中,ER阅读框得以保留,并编码一个较小的突变型ER,这可能是残留雌二醇结合的来源。当这种突变形式在体外过表达并进行表征时,它会产生一个预测大小的较小蛋白质,与野生型ER相比,其雌激素依赖性转录活性显著降低。尽管存在受损的ER变体的残留量,但雌激素治疗未能诱导已知的雌激素作用的子宫标志物,如DNA合成增加以及孕激素受体、乳铁蛋白和葡萄糖-6-磷酸脱氢酶基因的转录,从而证实了雌性ERKO小鼠对雌激素不敏感。此外,ERKO雌性小鼠的血清雌二醇水平比野生型高10倍以上,这与激素不敏感综合征一致。